Immunosuppression management for refractory checkpoint inhibitor-related hepatotoxicity.
Publication
, Journal Article
Karim, G; Reddy, M; Mobin, N; Weisberg, I; Dinani, A
Published in: Clin Liver Dis (Hoboken)
2024
Duke Scholars
Published In
Clin Liver Dis (Hoboken)
DOI
ISSN
2046-2484
Publication Date
2024
Volume
23
Issue
1
Start / End Page
e0096
Location
United States
Citation
APA
Chicago
ICMJE
MLA
NLM
Karim, G., Reddy, M., Mobin, N., Weisberg, I., & Dinani, A. (2024). Immunosuppression management for refractory checkpoint inhibitor-related hepatotoxicity. Clin Liver Dis (Hoboken), 23(1), e0096. https://doi.org/10.1097/CLD.0000000000000096
Karim, Gres, Megha Reddy, Navim Mobin, Ilan Weisberg, and Amreen Dinani. “Immunosuppression management for refractory checkpoint inhibitor-related hepatotoxicity.” Clin Liver Dis (Hoboken) 23, no. 1 (2024): e0096. https://doi.org/10.1097/CLD.0000000000000096.
Karim G, Reddy M, Mobin N, Weisberg I, Dinani A. Immunosuppression management for refractory checkpoint inhibitor-related hepatotoxicity. Clin Liver Dis (Hoboken). 2024;23(1):e0096.
Karim, Gres, et al. “Immunosuppression management for refractory checkpoint inhibitor-related hepatotoxicity.” Clin Liver Dis (Hoboken), vol. 23, no. 1, 2024, p. e0096. Pubmed, doi:10.1097/CLD.0000000000000096.
Karim G, Reddy M, Mobin N, Weisberg I, Dinani A. Immunosuppression management for refractory checkpoint inhibitor-related hepatotoxicity. Clin Liver Dis (Hoboken). 2024;23(1):e0096.
Published In
Clin Liver Dis (Hoboken)
DOI
ISSN
2046-2484
Publication Date
2024
Volume
23
Issue
1
Start / End Page
e0096
Location
United States